BioNTech’s Bold Leap: From COVID-19 Vaccine to Pioneering Cancer Therapies
BioNTech transitions focus from COVID-19 vaccines to mRNA-based cancer therapies, influencing financial dynamics. Despite a 2024 earnings decline, BioNTech outperformed market expectations with €1.08 per share, surpassing the anticipated €0.407.…